Share on StockTwits

Celgene Corp. (NASDAQ:CELG)‘s stock had its “buy” rating reaffirmed by analysts at TheStreet in a research report issued to clients and investors on Monday, Stock Ratings News reports.

The analysts wrote, “Celgene Corporation (CELG) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Celgene Corp. in a research note on Tuesday, February 4th. They now have a $162.00 price target on the stock. Separately, analysts at Guggenheim cut their price target on shares of Celgene Corp. from $193.00 to $191.00 in a research note on Friday, January 31st. Finally, analysts at BMO Capital Markets raised their price target on shares of Celgene Corp. from $200.00 to $211.00 in a research note on Friday, January 31st. They now have an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and sixteen have assigned a buy rating to the company’s stock. Celgene Corp. currently has an average rating of “Buy” and an average price target of $176.14.

Shares of Celgene Corp. (NASDAQ:CELG) opened at 162.31 on Monday. Celgene Corp. has a 52-week low of $98.62 and a 52-week high of $174.66. The stock’s 50-day moving average is $161.7 and its 200-day moving average is $155.. The company has a market cap of $65.901 billion and a P/E ratio of 47.77.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 30th. The company reported $1.51 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.54 by $0.03. The company had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.72 billion. On average, analysts predict that Celgene Corp. will post $7.29 earnings per share for the current fiscal year.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.